NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
29/07/2026
Voltar para busca
Dado oficial do USPTO
ABTIS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
29/07/2026
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
19/06/2019
Data de registro
12/05/2020
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
29/07/2026
Última transação
29/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
708
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
Suwon-si Gyeonggi-do, KR
Examinador
SETTLES LEWIS, SHAILA E
Localização atual
Historical data usage
Titulares e representantes
Titulares
AbTis Co., Ltd.
AbTis Co., Ltd.
Representantes
Paul G. Johnson Maschoff Brennan
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical agents affecting metabolism; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of cancer; chemical preparations for pharmaceutical purposesfor the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; biotechnological preparations for medical purposesfor the treatment of oncologicalmetabolic and ophthalmic diseases and disorders; drugs for medical purposesfor treating cancer; drugs for medical purposesfor treating diabetes; drugs for medical purposesfor treating ocular disease; antibodies for medical purposesfor the treatment of oncologicalmetabolic and ophthalmic diseases and disorders; pharmaceutical compositions for the treatment of oncologicalmetabolic and ophthalmic diseases and disorders; medicines for human purposes for the treatment of oncologicalmetabolic and ophthalmic diseases and disorders; nutraceuticals for therapeutic purposes for the treatment of cancer; nutraceuticals for therapeutic purposes for the treatment of diabetes; therapeutic drugs and agentsantibody drug conjugate comprising antibody and chemical compound attached for the treatment of oncologicalmetabolic and ophthalmic diseases and disorders; anti-cancer preparations
Classe 42
Research and development of vaccines and medicines; biotechnology research; biological research; crude medicines research; scientific research for medical purposes in the field of cancerous diseases; research on the subject of pharmaceuticals; medical research; clinical research in the field of oncologymetabolic disease and ophthalmology
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
29/07/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
27/07/2026
ES75
TEAS SECTION 71 & 15 RECEIVED
17/04/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/04/2026
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
12/05/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/01/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/10/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
17/09/2020
FIMP
FINAL DISPOSITION PROCESSED
17/09/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/08/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
12/05/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
25/02/2020
PUBO
PUBLISHED FOR OPPOSITION
25/02/2020
GPNX
NOTIFICATION PROCESSED BY IB
22/02/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/02/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/02/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/02/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
23/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/01/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/01/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/01/2020
RFNT
REFUSAL PROCESSED BY IB
16/11/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
31/10/2019
RFRR
REFUSAL PROCESSED BY MPU
31/10/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/10/2019
CNRT
NON-FINAL ACTION WRITTEN
11/10/2019
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
25/09/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
13/09/2019
CNRT
NON-FINAL ACTION WRITTEN
12/09/2019
DOCK
ASSIGNED TO EXAMINER
10/09/2019
MAFR
APPLICATION FILING RECEIPT MAILED
20/08/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
15/08/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/08/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ABTIS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.